Multiple Sclerosis | China In-Depth | China | 2021

Multiple sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence there. Traditionally, patients suffering from MS in China have been treated with two disease-modifying therapies (DMTs)—IFN-β-1b (Bayer’s Betaferon) and teriflunomide (Sanofi’s Aubagio)—and immunosuppressants such as methotrexate, mitoxantrone, rituximab, and azathioprine. The National Medical Products Administration is focused on granting fast-track designation to new therapies that address urgent clinical need in China, thus allowing such agents to move directly to the market-filing stage based on foreign clinical trial data, especially in the case of rare diseases. Recent inclusions of two S1PR modulators—fingolimod (Novartis’s Gilenya) and siponimod (Novartis’s Mayzent)—in the 2020 National Reimbursement Drug List will drive the uptake of these agents for MS in China, thus boosting overall market sales.


  • How large is China’s drug-treatable MS population, and how will the drug-treatment rate change during the forecast period?
  • Which are the most commercially relevant drugs in China’s MS market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
  • What are the market access considerations for key therapies in the MS pipeline in China? What sales / uptake could they secure in MS? What are interviewed experts’ opinions of key emerging therapies?
  • What are the key drivers and constraints in China’s MS therapy market, and how will the market evolve over the forecast period?


China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Release Date

October 2021



Primary Research

Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys of 50 neurologists.


Diagnosed prevalence of MS by country, with urban and rural breakup. Clinically relevant and market-relevant drug-treatable populations.


10-year, annualized, drug-level sales and patient share of key MS therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.

Emerging Therapies

Phase III/PR: 2+ drugs; Phase II: 2 drugs; coverage of select preclinical and Phase I products.

Login to access report